Clinical Trial Details
| Trial ID: | L6298 |
| Source ID: | NCT01124656 |
| Associated Drug: | Pioglitazone-Azilsartan |
| Title: | Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes |
| Acronym: | |
| Status: | TERMINATED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Pioglitazone-Azilsartan |
| Outcome Measures: | Primary: Incidence of Adverse Events., The Incidence of Treatment-Emergent Adverse Events, with an incidence \> 5%., On Occurrence (up to 52 Weeks). | Secondary: Change from Baseline for Glycosylated Hemoglobin., The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated including final visit, and Glycosylated Hemoglobin collected at baseline., Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48 and 52. |
| Sponsor/Collaborators: | Sponsor: Takeda |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 26 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2006-09 |
| Completion Date: | 2007-05 |
| Results First Posted: | |
| Last Update Posted: | 2012-05-21 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT01124656 |
